Skip to content
DataLookout
Menu

NCT07810309

Metabolic Impact of Pancreatic Duct Decompression

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change.

  1. Minor Start date changed from estimate of Sep 30, 2026 to Oct 30, 2026
  2. Notable Recruitment opened
    • Study sites: 0 to 1
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Feasibility of performing randomized-controlled trial in patients with minimally symptomatic chronic pancreatitis to assess metabolic function as defined via enrollment ratio, retention rate, and assessment completion rate.
Timeframe: From enrollment to 6 months post-randomization

Secondary (2)

Impact of pancreatic duct decompression on pancreatic endocrine function as measured via insulin secretion.
Impact of pancreatic duct decompression on pancreatic exocrine function as measured by fecal elastase.

Arms and interventions

Endoscopic pancreatic duct decompression (Intervention Arm)Experimental

Participants in the intervention arm will receive endoscopic pancreatic duct decompression.

No endoscopic intervention (Control Arm)No intervention

The control arm will receive medical management alone, defined as standard of care treatment per the discretion of the treating pancreatologist.

Procedures: Endoscopic pancreatic duct decompression

Sites

1 site in 1 country

  • Mayo ClinicRochester, Minnesota, United States